Table 2.

Cox proportional hazards—main effects for ε4 carrier status. Outcome: probable AD

Predictor variables	Main effects (unadjusted) hazard ratio (95% CI)	Main effects adjusteda hazard ratio (95% CI)	Main effects adjustedb hazard ratio (95% CI)
ε4 carrier	1.92 (1.54–2.41)**	2.55 (2.02–3.21)**	2.56 (2.03–3.23)**
Use of an anxiolytic	1.90 (.921–3.91)	2.35 (1.10–5.00)*	1.79 (.837–3.85)
Did not use anxiolytic	2.02 (1.58–2.58)**	2.67 (2.07–3.43)**	2.18 (1.69–2.82)**
- Alprazolam	2.27 (.504–10.22)	4.52 (.746–27.41)	2.54 (.405–15.90)
- No Alprazolam use	1.99 (1.57–2.51)**	2.64 (2.07–3.36)**	2.20 (1.72–2.81)**
- Clonazapam use	4.49 (.280–71.84)	—	—
- No Clonazapam use	1.99 (1.58–2.52)**	2.65 (2.09–3.37)**	2.21 (1.73–2.81)**
- Lorazapam use	1.60 (.357–7.15)	1.85 (.400–8.56)	1.07 (.196–5.85)
- No Lorazapam use	2.00 (1.58–2.53)**	2.67 (2.10–3.40)**	2.21 (1.73–2.82)**
- Paroxetine use	5.48 (1.22–24.72)*	5.70 (1.04–31.15)*	5.88 (1.04–33.06)*
- No Paroxetine use	1.96 (1.55–2.48)**	2.62 (2.05–3.33)**	2.15 (1.68–2.74)**
- Venlafaxine use	1.18 (.216–6.48)	1.69 (.253–11.26)	2.51 (.273–23.04)
- No Venlafaxine use	2.01 (1.59–2.55)**	2.68 (2.11–3.41)**	2.21 (1.73–2.83)**

^aAdjusted for sex, age, education, race, and Hispanic origin.

^bAdjusted for sex, age, education, race, Hispanic origin, and AD medication use.

^*Indicates statistical significance at p <.05.

^**Indicates p <0.001.

— indicates sample size too small for analysis.